Mitochondrial Pyruvate Carrier Inhibition to Force Metabolic Reprogramming Toward Ketone Utilization

MPC1/MPC2 metabolomics market 36% proposed
Composite
35%
Novelty
50%
Feasibility
40%
Impact
40%
Mechanistic
40%
Druggability
45%
Safety
30%
Confidence
30%

Mechanistic description

Mitochondrial Pyruvate Carrier Inhibition to Force Metabolic Reprogramming Toward Ketone Utilization

Evidence for (4)

  • MPC1 mRNA upregulation in human AD brain (computational: GTEx Brain Tissue Expression Database)

    PMID:GTEx

  • Pharmaceutical MPC inhibition protects against ischemia-reperfusion injury by activating protective metabolic pathways

    PMID:29425851

  • Forcing ketone body utilization activates BDNF signaling and enhances mitochondrial biogenesis

    PMID:25516598

  • Cancer metabolism literature confirms MPC inhibition shifts cells toward glutamine and fatty acid oxidation

    PMID:24393791

Evidence against (4)

  • MPC1 mRNA upregulation is computational annotation, not peer-reviewed validation - foundational claim lacks rigorous support

  • MPC inhibition reduces neuronal firing rates in vitro - neurons are highly dependent on glucose-derived pyruvate oxidation

    PMID:29425851

  • Forcing ketone utilization in already-metabolically-compromised neurons risks acute energy failure

  • Cancer metabolism literature does not translate directly - adult neurons are post-mitotic with different metabolic priorities